Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Generics
The disputes between manufacturers of original drugs and their Russian rivals may have a new twist in the local market, as the Russian Supreme Court has supported AstraZeneca in its legal fight with Jodas Expoim – a Russian subsidiary of Indian firm Jodas Expoim Pvt Ltd – by the ordering withdrawal of the certificate for its generic copy of Iressa (gefitinib), reports The Pharma Letter’s local correspondent. 2 September 2019
Pharmaceutical
By Dr Nicola Davies
September 7th is World Duchenne Awareness Day and the perfect opportunity to delve into the details of Duchenne muscular dystrophy (DMD) and pharma’s role in helping individuals living with this condition. 30 August 2019
Generics
Even as the Health Ministry is slated to exempt a popular contraceptive fixed dose combination (FDC) of centchroman and ethinyloestradiol from the Schedule H category (which has drugs that cannot be purchased over the counter without a valid prescription), a Central Drugs Standard Control Organization (CDSCO) expert committee is looking to further ban another lot of 324 FDCs, reports The Pharma Letter’s India correspondent. 30 August 2019
Biotechnology
The UK’s departure from the European Union looks likely to dent many sectors at least in the short to medium term, but the biopharmaceutical industry is one that might just continue to shine, however damaging the exit from the trade bloc proves to be. 23 August 2019
Pharmaceutical
Walk into any pharma company office in Japan and you will most likely see a plaque on a wall outlining the company’s mission. One of the statements will say: “Everything we do is to benefit patients,” notes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 20 August 2019
Pharmaceutical
UK-based Mundipharma is a unique player in healthcare, with Marco Cerato, its senior vice president, business development and strategic partnerships, telling The Pharma Letter that it “has always functioned slightly differently to other pharma companies.” 19 August 2019
Pharmaceutical
Even as the world's largest vaccine manufacturer by volume of doses Serum Institute of India and the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, have teamed up to create the first ever heat-stable rotavirus vaccine, many states in India have launched vaccination drives against rotavirus infections, a significant driver of child mortality in India, reports The Pharma Letter’s local correspondent. 19 August 2019
Pharmaceutical
The Delhi High Court has allowed Alembic Pharmaceuticals and Natco Pharma to export sorafenib, an active ingredient in German pharma major Bayer’s cancer drug Nexavar, and rivaroxaban, the API in its blood thinner medicine Xarelto, for research and development purposes. 19 August 2019
Pharmaceutical
Ensuring that the actions, messages and objectives of pharma companies and representative national and regional associations are aligned with the needs of patients and health systems in Latin America. 16 August 2019
Pharmaceutical
By Dr Nicola Davies
Labeling information, including product inserts, are important components of marketed drug products. Clear and complete labeling information is critical for both health professionals and patients to make informed decisions. It also ensures consumers are aware of the correct use of these medications to maintain safety and achieve the intended effectiveness. The importance of appropriate labeling information is highlighted by the US Food and Drug Administration’s recent actions to optimize labeling content for prescription drugs, including biologicals. 13 August 2019
Generics
Russian drugmaker R-Pharm is expanding its line of generics of original drugs by starting production of an analogue of Sevoran (sevoflurane), which is an anesthetic produced by the US biopharma company AbbVie. 13 August 2019
Pharmaceutical
Russian hospitals may face with a shortage of some vital and other drugs this year, due to massive disruptions in public procurements, according to recent statements by representatives of hospitals, reports The Pharma Letter’s local correspondent. 13 August 2019
Pharmaceutical
Anthony Barron, principal of the life sciences practice of Charles River Associates, considers how to better position European healthcare systems to support innovation in a sustainable way, in an Expert View column. 9 August 2019
Pharmaceutical
The Russian pharmaceutical market may face a steep decline in the second half of the current year, due to the ongoing slumping of drug sales in the country, according to recent statements by some senior state officials and industry’s analysts, reports The Pharma Letter’s local correspondent. 6 August 2019
Generics
The Russian government plans to accelerate its efforts aimed at raising exports of domestic drugs and active ingredients by 2030, reports The Pharma Letter’s local correspondent. 6 August 2019
Pharmaceutical
The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. 5 August 2019
Pharmaceutical
The National List of Essential Medicines (NLEM) in India, which determines the basis of drug price regulation, is set to add new medicines for the treatment of cardiac diseases and cancer along with certain antibiotics to its list. This would result in a massive slash in prices for these drugs, reports The Pharma Letter’s India correspondent. 1 August 2019
Pharmaceutical
It may sound surprising, but the most common form of poisoning in the UK is from medication according to NHS figures and children under five are most at risk. 30 July 2019
Biotechnology
A look at the potential of microbiome-based therapies to transform medicine, and the progress of the closest such treatment to market. 30 July 2019
Biotechnology
Russian drugmaker Biocad is expanding into the therapeutic area of psoriatic drugs, through the launch of production of its new treatment Efleira (netakimab), according to recent statements by the company, reports The Pharma Letter’s local correspondent. 29 July 2019
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze